• SPX
  • $5,973.10
  • 0.74 %
  • $44.06
  • DJI
  • $43,811.72
  • 0.19 %
  • $82.38
  • N225
  • $39,500.37
  • 0.3 %
  • $118.96
  • FTSE
  • $8,095.53
  • -0.56 %
  • -$45.21
  • IXIC
  • $19,292.98
  • 0.12 %
  • $23.52
Omega Therapeutics, Inc. (OMGA) Stock Price, News & Analysis

Omega Therapeutics, Inc. (OMGA) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.08

-$0.04

(-3.51%)

Day's range
$1.08
Day's range
$1.1
50-day range
$0.89
Day's range
$1.69
  • Country: US
  • ISIN: US68217N1054
52 wk range
$0.89
Day's range
$6.3


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -4.19
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (OMGA)
  • Company Omega Therapeutics, Inc.
  • Price $1.08
  • Changes Percentage (-3.51%)
  • Change -$0.04
  • Day Low $1.08
  • Day High $1.10
  • Year High $6.30

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/07/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $9.00
  • High Stock Price Target $11.00
  • Low Stock Price Target $7.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.66
  • Trailing P/E Ratio -1.2
  • Forward P/E Ratio -1.2
  • P/E Growth -1.2
  • Net Income $-97,428,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.